XML 67 R11.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases (Notes)
 3 Months Ended
Dec. 28, 2019
Leases [Abstract]  
Leases Leases
Lessee Activity - Leases where Hologic is the Lessee

The majority of the Company's facilities are occupied under operating lease arrangements with various expiration dates through 2035, some of which include options to extend the life of the lease, and some of which include options to terminate the lease within one year. The Company has operating leases for office space, land, warehouse and manufacturing space, vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. For leases executed in fiscal 2020 and later, the Company accounts for the lease components and the non-lease components as a single lease component. The Company's leases have remaining lease terms of one year to approximately 15 years, some of which may include options to extend the leases for up to 20 years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company does not have any leases that include residual value guarantees.

The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of an arrangement. The right-of-use assets and related liabilities for operating leases are included in other assets, accrued expenses, and other long-term liabilities in the consolidated balance sheet as of December 28, 2019. As a result of the Cynosure acquisition, the Company has a finance lease for the facility that was previously Cynosure's U.S. headquarters. This lease was recorded as a capital lease under ASC 840 as of September 28, 2019. The right-of-use asset for the finance lease is included in property, plant and equipment, and the short-term and long-term liability are presented separately in the consolidated balance sheet as of December 28, 2019.
    
Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The weighted average discount rate utilized on the Company's operating and finance lease liabilities as of December 28, 2019 was 2.57%.

The following table presents supplemental balance sheet information related to the Company's operating and finance leases:
 
 
 
December 28, 2019
 
 
Balance Sheet Location
Operating Leases
Finance Lease
Assets
 
 
 
 
Lease right-of-use assets
 
Other assets
$
89.6

$
—

Lease right-of-use assets
 
Property, plant and equipment
$
—

9.9

Liabilities
 
 
 
 
Operating lease liabilities (current)
 
Accrued expenses

$
22.2

$
—

Finance lease liabilities (current)
 
Finance lease obligations - short term
$
—

$
1.8

Operating lease liabilities (non-current)
 
Other long-term liabilities

$
72.3

$
—

Finance lease liabilities (non-current)
 
Finance lease obligations - long term

$
—

$
18.8



The finance lease was previously recorded as a capital lease in the consolidated balance at September 28, 2019, and the short-term and long-term liabilities were $1.8 million and $19.2 million, respectively.

The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases:

 
 
December 28, 2019
 
 
Operating Leases
Finance Lease
Weighted average remaining lease term
 
6.09

8.39

Weighted average discount rate
 
1.93
%
5.1
%


The following table provides information related to the Company’s operating and finance leases:

 
 
Three Months Ended
 
 
December 28, 2019
Operating lease cost (a)
$
7.0

Finance lease cost - amortization of right-of-use assets
$
0.3

Finance lease cost - interest cost
$
0.3

Cash paid for amounts included in the measurement of lease liabilities:
 
 
Operating cash flows from finance leases
$
0.3

 
Operating cash flows from operating leases
5.9

 
Financing cash flows from finance leases
$
0.4

 
Total cash paid for amounts included in the measurement of lease liabilities
$
6.6

 
 
 
ROU assets arising from entering into new operating lease obligations
$
1.4

(a) Includes short-term lease expense and variable lease costs, which were immaterial in the three months ended December 28, 2019.
During the three months ended December 28, 2019, the non-cash impact of remeasuring the Company's right-of-use assets and operating lease liabilities was $2.4 million.
The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance lease as of December 28, 2019:
Fiscal Year
 
Operating Leases
Finance Lease
2020 remaining
 
$
17.8

$
2.1

2021
 
22.2

2.8

2022
 
17.3

3.0

2023
 
10.7

3.0

2024
 
8.7

3.0

Thereafter
 
24.0

11.5

Total future minimum lease payments
 
100.7

25.4

Less: imputed interest
 
(6.2
)
(4.8
)
Present value of lease liabilities
 
$
94.5

$
20.6


Lessor Activity - Leases where Hologic is the Lessor

Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as performance obligations for reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Sales-type leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented approximately 3% of the Company’s consolidated revenue for the three months ended December 28, 2019.
Leases Leases
Lessee Activity - Leases where Hologic is the Lessee

The majority of the Company's facilities are occupied under operating lease arrangements with various expiration dates through 2035, some of which include options to extend the life of the lease, and some of which include options to terminate the lease within one year. The Company has operating leases for office space, land, warehouse and manufacturing space, vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. For leases executed in fiscal 2020 and later, the Company accounts for the lease components and the non-lease components as a single lease component. The Company's leases have remaining lease terms of one year to approximately 15 years, some of which may include options to extend the leases for up to 20 years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company does not have any leases that include residual value guarantees.

The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of an arrangement. The right-of-use assets and related liabilities for operating leases are included in other assets, accrued expenses, and other long-term liabilities in the consolidated balance sheet as of December 28, 2019. As a result of the Cynosure acquisition, the Company has a finance lease for the facility that was previously Cynosure's U.S. headquarters. This lease was recorded as a capital lease under ASC 840 as of September 28, 2019. The right-of-use asset for the finance lease is included in property, plant and equipment, and the short-term and long-term liability are presented separately in the consolidated balance sheet as of December 28, 2019.
    
Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The weighted average discount rate utilized on the Company's operating and finance lease liabilities as of December 28, 2019 was 2.57%.

The following table presents supplemental balance sheet information related to the Company's operating and finance leases:
 
 
 
December 28, 2019
 
 
Balance Sheet Location
Operating Leases
Finance Lease
Assets
 
 
 
 
Lease right-of-use assets
 
Other assets
$
89.6

$
—

Lease right-of-use assets
 
Property, plant and equipment
$
—

9.9

Liabilities
 
 
 
 
Operating lease liabilities (current)
 
Accrued expenses

$
22.2

$
—

Finance lease liabilities (current)
 
Finance lease obligations - short term
$
—

$
1.8

Operating lease liabilities (non-current)
 
Other long-term liabilities

$
72.3

$
—

Finance lease liabilities (non-current)
 
Finance lease obligations - long term

$
—

$
18.8



The finance lease was previously recorded as a capital lease in the consolidated balance at September 28, 2019, and the short-term and long-term liabilities were $1.8 million and $19.2 million, respectively.

The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases:

 
 
December 28, 2019
 
 
Operating Leases
Finance Lease
Weighted average remaining lease term
 
6.09

8.39

Weighted average discount rate
 
1.93
%
5.1
%


The following table provides information related to the Company’s operating and finance leases:

 
 
Three Months Ended
 
 
December 28, 2019
Operating lease cost (a)
$
7.0

Finance lease cost - amortization of right-of-use assets
$
0.3

Finance lease cost - interest cost
$
0.3

Cash paid for amounts included in the measurement of lease liabilities:
 
 
Operating cash flows from finance leases
$
0.3

 
Operating cash flows from operating leases
5.9

 
Financing cash flows from finance leases
$
0.4

 
Total cash paid for amounts included in the measurement of lease liabilities
$
6.6

 
 
 
ROU assets arising from entering into new operating lease obligations
$
1.4

(a) Includes short-term lease expense and variable lease costs, which were immaterial in the three months ended December 28, 2019.
During the three months ended December 28, 2019, the non-cash impact of remeasuring the Company's right-of-use assets and operating lease liabilities was $2.4 million.
The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance lease as of December 28, 2019:
Fiscal Year
 
Operating Leases
Finance Lease
2020 remaining
 
$
17.8

$
2.1

2021
 
22.2

2.8

2022
 
17.3

3.0

2023
 
10.7

3.0

2024
 
8.7

3.0

Thereafter
 
24.0

11.5

Total future minimum lease payments
 
100.7

25.4

Less: imputed interest
 
(6.2
)
(4.8
)
Present value of lease liabilities
 
$
94.5

$
20.6


Lessor Activity - Leases where Hologic is the Lessor

Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as performance obligations for reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Sales-type leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented approximately 3% of the Company’s consolidated revenue for the three months ended December 28, 2019.
Leases Leases
Lessee Activity - Leases where Hologic is the Lessee

The majority of the Company's facilities are occupied under operating lease arrangements with various expiration dates through 2035, some of which include options to extend the life of the lease, and some of which include options to terminate the lease within one year. The Company has operating leases for office space, land, warehouse and manufacturing space, vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. For leases executed in fiscal 2020 and later, the Company accounts for the lease components and the non-lease components as a single lease component. The Company's leases have remaining lease terms of one year to approximately 15 years, some of which may include options to extend the leases for up to 20 years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company does not have any leases that include residual value guarantees.

The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of an arrangement. The right-of-use assets and related liabilities for operating leases are included in other assets, accrued expenses, and other long-term liabilities in the consolidated balance sheet as of December 28, 2019. As a result of the Cynosure acquisition, the Company has a finance lease for the facility that was previously Cynosure's U.S. headquarters. This lease was recorded as a capital lease under ASC 840 as of September 28, 2019. The right-of-use asset for the finance lease is included in property, plant and equipment, and the short-term and long-term liability are presented separately in the consolidated balance sheet as of December 28, 2019.
    
Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The weighted average discount rate utilized on the Company's operating and finance lease liabilities as of December 28, 2019 was 2.57%.

The following table presents supplemental balance sheet information related to the Company's operating and finance leases:
 
 
 
December 28, 2019
 
 
Balance Sheet Location
Operating Leases
Finance Lease
Assets
 
 
 
 
Lease right-of-use assets
 
Other assets
$
89.6

$
—

Lease right-of-use assets
 
Property, plant and equipment
$
—

9.9

Liabilities
 
 
 
 
Operating lease liabilities (current)
 
Accrued expenses

$
22.2

$
—

Finance lease liabilities (current)
 
Finance lease obligations - short term
$
—

$
1.8

Operating lease liabilities (non-current)
 
Other long-term liabilities

$
72.3

$
—

Finance lease liabilities (non-current)
 
Finance lease obligations - long term

$
—

$
18.8



The finance lease was previously recorded as a capital lease in the consolidated balance at September 28, 2019, and the short-term and long-term liabilities were $1.8 million and $19.2 million, respectively.

The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases:

 
 
December 28, 2019
 
 
Operating Leases
Finance Lease
Weighted average remaining lease term
 
6.09

8.39

Weighted average discount rate
 
1.93
%
5.1
%


The following table provides information related to the Company’s operating and finance leases:

 
 
Three Months Ended
 
 
December 28, 2019
Operating lease cost (a)
$
7.0

Finance lease cost - amortization of right-of-use assets
$
0.3

Finance lease cost - interest cost
$
0.3

Cash paid for amounts included in the measurement of lease liabilities:
 
 
Operating cash flows from finance leases
$
0.3

 
Operating cash flows from operating leases
5.9

 
Financing cash flows from finance leases
$
0.4

 
Total cash paid for amounts included in the measurement of lease liabilities
$
6.6

 
 
 
ROU assets arising from entering into new operating lease obligations
$
1.4

(a) Includes short-term lease expense and variable lease costs, which were immaterial in the three months ended December 28, 2019.
During the three months ended December 28, 2019, the non-cash impact of remeasuring the Company's right-of-use assets and operating lease liabilities was $2.4 million.
The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance lease as of December 28, 2019:
Fiscal Year
 
Operating Leases
Finance Lease
2020 remaining
 
$
17.8

$
2.1

2021
 
22.2

2.8

2022
 
17.3

3.0

2023
 
10.7

3.0

2024
 
8.7

3.0

Thereafter
 
24.0

11.5

Total future minimum lease payments
 
100.7

25.4

Less: imputed interest
 
(6.2
)
(4.8
)
Present value of lease liabilities
 
$
94.5

$
20.6


Lessor Activity - Leases where Hologic is the Lessor

Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as performance obligations for reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Sales-type leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented approximately 3% of the Company’s consolidated revenue for the three months ended December 28, 2019.
Leases Leases
Lessee Activity - Leases where Hologic is the Lessee

The majority of the Company's facilities are occupied under operating lease arrangements with various expiration dates through 2035, some of which include options to extend the life of the lease, and some of which include options to terminate the lease within one year. The Company has operating leases for office space, land, warehouse and manufacturing space, vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. For leases executed in fiscal 2020 and later, the Company accounts for the lease components and the non-lease components as a single lease component. The Company's leases have remaining lease terms of one year to approximately 15 years, some of which may include options to extend the leases for up to 20 years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company does not have any leases that include residual value guarantees.

The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of an arrangement. The right-of-use assets and related liabilities for operating leases are included in other assets, accrued expenses, and other long-term liabilities in the consolidated balance sheet as of December 28, 2019. As a result of the Cynosure acquisition, the Company has a finance lease for the facility that was previously Cynosure's U.S. headquarters. This lease was recorded as a capital lease under ASC 840 as of September 28, 2019. The right-of-use asset for the finance lease is included in property, plant and equipment, and the short-term and long-term liability are presented separately in the consolidated balance sheet as of December 28, 2019.
    
Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The weighted average discount rate utilized on the Company's operating and finance lease liabilities as of December 28, 2019 was 2.57%.

The following table presents supplemental balance sheet information related to the Company's operating and finance leases:
 
 
 
December 28, 2019
 
 
Balance Sheet Location
Operating Leases
Finance Lease
Assets
 
 
 
 
Lease right-of-use assets
 
Other assets
$
89.6

$
—

Lease right-of-use assets
 
Property, plant and equipment
$
—

9.9

Liabilities
 
 
 
 
Operating lease liabilities (current)
 
Accrued expenses

$
22.2

$
—

Finance lease liabilities (current)
 
Finance lease obligations - short term
$
—

$
1.8

Operating lease liabilities (non-current)
 
Other long-term liabilities

$
72.3

$
—

Finance lease liabilities (non-current)
 
Finance lease obligations - long term

$
—

$
18.8



The finance lease was previously recorded as a capital lease in the consolidated balance at September 28, 2019, and the short-term and long-term liabilities were $1.8 million and $19.2 million, respectively.

The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases:

 
 
December 28, 2019
 
 
Operating Leases
Finance Lease
Weighted average remaining lease term
 
6.09

8.39

Weighted average discount rate
 
1.93
%
5.1
%


The following table provides information related to the Company’s operating and finance leases:

 
 
Three Months Ended
 
 
December 28, 2019
Operating lease cost (a)
$
7.0

Finance lease cost - amortization of right-of-use assets
$
0.3

Finance lease cost - interest cost
$
0.3

Cash paid for amounts included in the measurement of lease liabilities:
 
 
Operating cash flows from finance leases
$
0.3

 
Operating cash flows from operating leases
5.9

 
Financing cash flows from finance leases
$
0.4

 
Total cash paid for amounts included in the measurement of lease liabilities
$
6.6

 
 
 
ROU assets arising from entering into new operating lease obligations
$
1.4

(a) Includes short-term lease expense and variable lease costs, which were immaterial in the three months ended December 28, 2019.
During the three months ended December 28, 2019, the non-cash impact of remeasuring the Company's right-of-use assets and operating lease liabilities was $2.4 million.
The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance lease as of December 28, 2019:
Fiscal Year
 
Operating Leases
Finance Lease
2020 remaining
 
$
17.8

$
2.1

2021
 
22.2

2.8

2022
 
17.3

3.0

2023
 
10.7

3.0

2024
 
8.7

3.0

Thereafter
 
24.0

11.5

Total future minimum lease payments
 
100.7

25.4

Less: imputed interest
 
(6.2
)
(4.8
)
Present value of lease liabilities
 
$
94.5

$
20.6


Lessor Activity - Leases where Hologic is the Lessor

Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as performance obligations for reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Sales-type leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented approximately 3% of the Company’s consolidated revenue for the three months ended December 28, 2019.